Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases including chronic and acute gout, announced today management will be ...
In patients with gout, a novel prediction tool that relies on weight and creatinine clearance successfully identified the ...
These Phase 3 clinical studies are designed to evaluate the safety and efficacy of dotinurad compared to an active control ...
Urica Therapeutics, a majority-owned subsidiary of Fortress, reported that Crystalys Therapeutics has dosed the first patients in two global Phase 3 trials evaluating dotinurad, a once-daily oral ...
The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback